GlaxoSmithKline Pharmaceuticals Limited (GSK), a subsidiary of the UK-based GSK Plc, primarily engages in manufacturing and trading pharmaceutical products and vaccines. Operating with a strong presence in India, GSK focuses on segments like general medicines, vaccines, and specialization in oncology.

The recent launch of Jemperli and Zejula marks GSK's strategic re-entry into the oncology market, addressing unmet needs in gynecological cancers such as endometrial and ovarian cancers, signaling a robust commitment to innovation in cancer therapies.

GSK's strategic acquisition of Novartis' vaccines business has significantly bolstered its vaccine portfolio, highlighting the company's pursuit of expanding its virology expertise and reinforcing its global position in the vaccines market.

Despite facing supply chain disruptions and regulatory impacts, GSK demonstrated resilience with significant growth in its specialty and vaccines segments, achieving improved profit margins and a robust portfolio transformation.

The company has showcased a strong cultural transformation with a focus on driving growth through digital innovation and partnerships with healthcare providers, especially in the adult immunization segment.